Drug Patents owned by Palatin Technologies
1. List of Vyleesi (autoinjector) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6794489 | PALATIN TECHNOLOGIES | Compositions and methods for treatment of sexual dysfunction |
Jun, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9352013 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(10 years from now) | |
| US9700592 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(10 years from now) | |
| US10286034 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 21, 2024 |
Drugs and Companies using BREMELANOTIDE ACETATE ingredient
NCE-1 date: June, 2023
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of hypoactive sexual desire disorder (hsdd)
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic